CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
N/A Nivolumab and Ipilimumab Melanoma (Skin) Active
Jemperli dostarlimab Endometrial cancer Active
Awiqli insulin icodec Diabetes mellitus, type 2 Active
Bimzelx bimekizumab Ankylosing spondylitis Active
TBC ruxolitinib atopic dermatitis Suspended
Prevymis letermovir Cytomegalovirus infection (CMV), prophylaxis Active
TBC lebrikizumab atopic dermatitis Active
Opdivo nivolumab Stage IIB or IIC melanoma, adjuvant Active
Elrexfio elranatamab Relapsed or refractory multiple myeloma Active
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Active
Last Updated : May 9, 2024